Dr. Robert Devenyi MD, FRCSC, FACS
Professor and Chief of Ophthalmology, UNIVERSITY OF TORONTO
Member of the Healthcare Council
Council Member Biography
Robert Devenyi, MD, MBA, FRCSC, FACS, is a Professor of Ophthalmology and Vision Sciences at The University of Toronto, Canada. Dr. Devenyi is the Director of the Donald K. Johnson Eye Center, Director of Retinal Services at University Health Network and Ophthalmologist-in-Chief at the University Health Network, The University of Toronto. He is also the Team Ophthalmologist for The Toronto Maple Leafs. Dr. Devenyi has experience in all aspects of adult and pediatric vitreoretinal surgery, anti-VEGF agents, and rheopheresis, and has been a consultant in these fields. He is also a member of the Clinical Studies Resource Centre of Toronto Western Research Institute. Dr. Devenyi's research focuses on the development of a novel treatment for neovascular age-related macular degeneration, involving ultra high speed indocyanine angiography and a coupled diode laser, the surgical repair of complex retinal detachments, diabetic retinopathy, and all aspects of macular degeneration. (This is me - Update Profile)
Employment History
- 2001 - Unspecified
- Professor and Chief of Ophthalmology, UNIVERSITY OF TORONTO
- 1993 - Unspecified
- Director of Retinal Services , UNIVERSITY HEALTH NETWORK
GLG NewsSM Analyses by Robert Devenyi
GLG News is now G+ Insights
-
G+ is a community for professionals, academics and entrepreneurs to connect through online discussions and in-person meetings. You will continue to see G+ Insights (formerly GLG News) here as well as on the G+ website, where you can share and discuss the G+ Insights you read.
-
It is morally reprehensible that the NEI was forced to act and create the CATT trial
March 11, 2008
Comparison of AMD Treatments Trials (CATT): Lucentis — Avastin Trial | www.pipelinereview.com
I agree...the present situation is really quite absurd...in most practices...IF a third party is willing to pay for Lucentis...patients usually get Lucentis...if patients have to pay themselves...they usually receive Avastin...despite there not being a shred of convincing evidence that Lucentis is superior to Avastin...in fact...most retinal specialists suspect that Avastin might will be superior...due to a longer duration of effect...and thus requiring less frequent injections...It is morally reprehensible that the CATT trial is happening because the NEI had to step in...Genentech refused to do the right thing and compare their two medicines...instead...and even worse...they tried...last November...unsuccessfully...to block compounding pharmacies from supplying Avastin to retinal specialists...
-
Genentech enrages vitreoretinal specialists
December 6, 2007
Genentech to cease supplying bevacizumab to compounding pharmacies | www.osnsupersite.com
-Retinal community unites against Genentech -both the American Association of Ophthalmology and the American Society of Retinal Specialists have condemned Genentech's actions -this represents profit-driven pharma at their worst -very poor decision by Genentech...not only to galvanize the profession they should be seeking to court against them...but also to put at risk hundreds of thousands of patients -myriad very interesting legal points are raised
-
Genentech has a huge problem with their credibility
February 15, 2007
Dear Doctor Letter regarding Lucentis | www.gene.com
Genentech should have voluntarily compared Lucentis with Avastin.
All of Genentech's efforts to promote Lucentis seem self serving and insincere.
Gerson Lehrman Group, Inc. connects communities with knowledge through two distinct, yet complementary offerings: GLG Research and G+.